743 related articles for article (PubMed ID: 17695274)
1. [Mechanisms of prion transmission].
Sakaguchi S
Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
[TBL] [Abstract][Full Text] [Related]
2. The state of the prion.
Weissmann C
Nat Rev Microbiol; 2004 Nov; 2(11):861-71. PubMed ID: 15494743
[TBL] [Abstract][Full Text] [Related]
3. The role of rafts in the fibrillization and aggregation of prions.
Pinheiro TJ
Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
[TBL] [Abstract][Full Text] [Related]
4. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
[TBL] [Abstract][Full Text] [Related]
5. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
6. Towards cellular receptors for prions.
Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
[TBL] [Abstract][Full Text] [Related]
7. Truncated PrP(c) in mammalian brain: interspecies variation and location in membrane rafts.
Laffont-Proust I; Hässig R; Haïk S; Simon S; Grassi J; Fonta C; Faucheux BA; Moya KL
Biol Chem; 2006 Mar; 387(3):297-300. PubMed ID: 16542151
[TBL] [Abstract][Full Text] [Related]
8. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
Sasaki K; Minaki H; Iwaki T
J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
[TBL] [Abstract][Full Text] [Related]
9. Differential solubility of prions is associated in manifold phenotypes.
Kuczius T; Karch H; Groschup MH
Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
[TBL] [Abstract][Full Text] [Related]
10. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
11. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
12. Physiopathologic implications of the structural and functional domains of the prion protein.
Sorgato MC; Bertoli A
Ital J Biochem; 2006; 55(3-4):222-31. PubMed ID: 17274528
[TBL] [Abstract][Full Text] [Related]
13. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
14. Altered prion protein glycosylation in the aging mouse brain.
Goh AX; Li C; Sy MS; Wong BS
J Neurochem; 2007 Feb; 100(3):841-54. PubMed ID: 17144900
[TBL] [Abstract][Full Text] [Related]
15. Prion proteins: a biological role beyond prion diseases.
Hu W; Rosenberg RN; Stüve O
Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
[TBL] [Abstract][Full Text] [Related]
16. PrP(Sc) of scrapie 263K propagates efficiently in spleen and muscle tissues with protein misfolding cyclic amplification.
Shi S; Dong CF; Wang GR; Wang X; An R; Chen JM; Shan B; Zhang BY; Xu K; Shi Q; Tian C; Gao C; Han J; Dong XP
Virus Res; 2009 Apr; 141(1):26-33. PubMed ID: 19162101
[TBL] [Abstract][Full Text] [Related]
17. Evolving views in prion glycosylation: functional and pathological implications.
Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
[TBL] [Abstract][Full Text] [Related]
18. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.
Saborio GP; Permanne B; Soto C
Nature; 2001 Jun; 411(6839):810-3. PubMed ID: 11459061
[TBL] [Abstract][Full Text] [Related]
19. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
[TBL] [Abstract][Full Text] [Related]
20. The metabolism of glycosaminoglycans is impaired in prion diseases.
Mayer-Sonnenfeld T; Zeigler M; Halimi M; Dayan Y; Herzog C; Lasmezas CI; Gabizon R
Neurobiol Dis; 2005 Dec; 20(3):738-43. PubMed ID: 15951190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
